Showing results (21-30 of 211) with videos related to
Sort By:
Pageof 22
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.Frontiers in Genetics|July 2, 2021
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast CancerDaniel L Hertz, Karen Lisa Smith, Yuhua Zong, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 29, 2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicityDaniel L Hertz, Maryam B Lustberg, Stephen SonisPharmacogenomics|April 10, 2018
CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administrationAmy L Pasternak, Lu Zhang, Daniel L HertzBreast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.Oral Diseases|December 4, 2020
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancerCatherine Van Poznak, Evan L Reynolds, Cherry L Estilo, et al.Breast Cancer Research : BCR|July 13, 2006
When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?Chad J Creighton, James M RaeBreast Cancer Research : BCR|November 11, 2005
What does an orphan G-protein-coupled receptor have to do with estrogen?James M Rae, Michael D JohnsonBreast Cancer Research and Treatment|March 5, 2004
Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitorsJames M Rae, Marc E LippmanPageof 22